Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a ...

Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy ...

The OrigAMI-1 study is assessing the efficacy and safety of RYBREVANT combined with chemotherapy regimens mFOLFOX6 or FOLFIRI ...

Factors related to sex and gender can affect therapy outcomes and should not be overlooked in clinical practice or research.

公开资料显示，恩考芬尼目前已经获美国FDA获批多项适应症，包括于2018年获批与比美替尼（binimetinib，Mektovi）组合疗法治疗带有BRAF ...

A summary of current health news including Walgreens settling fraud charges, FDA approval for Eli Lilly's eczema drug, links ...

Melanoma is a type of skin cancer that starts when pigment cells in the skin grow uncontrollably, rising for the last 30 ...

While neoadjuvant therapy in stage III or great melanoma is already the standard of care, new research presented at ESMO ...

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the 2024 update to the RELATIVITY-047 trial in advanced ...

周一，Stifel重申了对C4 Therapeutics (NASDAQ:CCCC)股票的买入评级，目标价为14.00美元。该公司的评估是在C4 Therapeutics的CFT1946初步数据发布之后做出的。CFT1946是一种用于治疗携带BRAF V600X突变的实体瘤的药物。这些数据在2024年欧洲肿瘤内科学会(ESMO24)的摘要中公布，符合Stifel的预期，并表明该药物在BRAF酪氨酸 ...